Difference of oncological efficacy between two immune checkpoint inhibitors following first-line platinum-based chemotherapy in patients with unresectable, metastatic, advanced urothelial carcinoma: a multicenter real-world Japanese cohort.
Avelumab
Chemotherapy
Kidney pelvis
Pembrolizumab
Ureter
Urinary bladder neoplasms
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
18 Jun 2024
18 Jun 2024
Historique:
received:
16
03
2024
accepted:
14
06
2024
medline:
18
6
2024
pubmed:
18
6
2024
entrez:
18
6
2024
Statut:
aheadofprint
Résumé
Maintenance avelumab is currently recommended for patients with unresectable and/or metastatic (mUC) achieving at least stable disease (SD) on first-line platinum-based chemotherapy (1L-CT). Pembrolizumab is an alternative therapeutic avenue for this patient cohort in clinical practice. We investigated real-world data, focusing on the correlation between response to 1L-CT and oncological efficacy of subsequent immune checkpoint inhibitor (ICI) therapy with avelumab or pembrolizumab. A multicenter database registered 626 patients with mUC diagnosed from 2008-2023; among these, 175 receiving 2-6 cycles of 1L-CT followed by ICI therapy. Patients were categorized based on response to 1L-CT using the Response Evaluation Criteria in Solid Tumors (v1.1). Objective response rate on ICI, progression to ICI-free survival (ICI-PFS), and overall survival from start of 1L-CT were compared between avelumab-treated and pembrolizumab-treated patients in each response subgroup. ICI-PFS was significantly longer in patients achieving partial response on 1L-CT and subsequently receiving pembrolizumab compared to those receiving avelumab. Notably, patients achieving SD on 1L-CT and subsequently receiving pembrolizumab manifested significantly higher objective response rate (14% and 41%, respectively) and prolonged ICI-PFS relative to those receiving avelumab. In contrast, overall survival did not delineate difference between patients treated with avelumab versus pembrolizumab. Similar findings were discerned in the subanalysis of patients having favorable SD (tumor shrinkage, from - 29 to 0%) and unfavorable SD (tumor enlargement, from + 1 to + 19%) on 1L-CT. Our study provides real-world evidence regarding difference of oncological efficacy between maintenance avelumab and subsequent pembrolizumab in patients with mUC who achieved partial response or SD on 1L-CT.
Sections du résumé
BACKGROUND
BACKGROUND
Maintenance avelumab is currently recommended for patients with unresectable and/or metastatic (mUC) achieving at least stable disease (SD) on first-line platinum-based chemotherapy (1L-CT). Pembrolizumab is an alternative therapeutic avenue for this patient cohort in clinical practice. We investigated real-world data, focusing on the correlation between response to 1L-CT and oncological efficacy of subsequent immune checkpoint inhibitor (ICI) therapy with avelumab or pembrolizumab.
METHODS
METHODS
A multicenter database registered 626 patients with mUC diagnosed from 2008-2023; among these, 175 receiving 2-6 cycles of 1L-CT followed by ICI therapy. Patients were categorized based on response to 1L-CT using the Response Evaluation Criteria in Solid Tumors (v1.1). Objective response rate on ICI, progression to ICI-free survival (ICI-PFS), and overall survival from start of 1L-CT were compared between avelumab-treated and pembrolizumab-treated patients in each response subgroup.
RESULTS
RESULTS
ICI-PFS was significantly longer in patients achieving partial response on 1L-CT and subsequently receiving pembrolizumab compared to those receiving avelumab. Notably, patients achieving SD on 1L-CT and subsequently receiving pembrolizumab manifested significantly higher objective response rate (14% and 41%, respectively) and prolonged ICI-PFS relative to those receiving avelumab. In contrast, overall survival did not delineate difference between patients treated with avelumab versus pembrolizumab. Similar findings were discerned in the subanalysis of patients having favorable SD (tumor shrinkage, from - 29 to 0%) and unfavorable SD (tumor enlargement, from + 1 to + 19%) on 1L-CT.
CONCLUSIONS
CONCLUSIONS
Our study provides real-world evidence regarding difference of oncological efficacy between maintenance avelumab and subsequent pembrolizumab in patients with mUC who achieved partial response or SD on 1L-CT.
Identifiants
pubmed: 38888683
doi: 10.1007/s10147-024-02573-5
pii: 10.1007/s10147-024-02573-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.
Références
Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249
doi: 10.3322/caac.21660
pubmed: 33538338
Matsuda T, Okuyama A (2017) Incidence rate for bladder cancer in Japanese in Japan and in the United States from the cancer incidence in five continents. Jpn J Clin Oncol 47:284–285
doi: 10.1093/jjco/hyx017
pubmed: 28204563
Miyake M, Nishimura N, Oda Y et al (2024) Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort. Jpn J Clin Oncol 54:329–338
doi: 10.1093/jjco/hyad170
pubmed: 38061911
Barthelemy P, Loriot Y, Voog E et al (2023) Full analysis from AVENANCE: a real-world study of avelumab first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC). J Clin Oncol. https://doi.org/10.1200/JCO.2023.41.6_suppl.471
doi: 10.1200/JCO.2023.41.6_suppl.471
Powles T, Park SH, Voog E et al (2020) Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 383:1218–1230
doi: 10.1056/NEJMoa2002788
pubmed: 32945632
Bellmunt J, de Wit R, Vaughn DJ et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376:1015–1026
doi: 10.1056/NEJMoa1613683
pubmed: 28212060
pmcid: 5635424
Alfred Witjes J, Max Bruins H, Carrión A et al (2024) European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 Guidelines. Eur Urol 85:17–31
doi: 10.1016/j.eururo.2023.08.016
pubmed: 37858453
Flaig TW, Spiess PE, Abern M et al (2022) NCCN Guidelines® insights: bladder cancer, Version 2.2022. J Natl Compr Canc Netw 20:866–878
doi: 10.6004/jnccn.2022.0041
pubmed: 35948037
Grivas P, Park SH, Voog E et al (2023) Avelumab first-line maintenance therapy for advanced urothelial carcinoma: comprehensive clinical subgroup analyses from the JAVELIN Bladder 100 Phase 3 Trial. Eur Urol 84:95–108
doi: 10.1016/j.eururo.2023.03.030
pubmed: 37121850
Galsky MD, Mortazavi A, Milowsky MI et al (2020) Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer. J Clin Oncol 38:1797–1806
doi: 10.1200/JCO.19.03091
pubmed: 32271672
pmcid: 7255983
Vellinga A, Cormican M, Hanahoe B et al (2011) Opt-out as an acceptable method of obtaining consent in medical research: a short report. BMC Med Res Methodol 11:40
doi: 10.1186/1471-2288-11-40
pubmed: 21470399
pmcid: 3079702
Miyake M, Shimizu T, Oda Y et al (2023) Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter study. Jpn J Clin Oncol 53:253–262
doi: 10.1093/jjco/hyac186
pubmed: 36484294
Pfister C, Gravis G, Flechon A et al (2024) Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study. Lancet Oncol 25:255–264
doi: 10.1016/S1470-2045(23)00587-9
pubmed: 38142702
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
doi: 10.1016/j.ejca.2008.10.026
pubmed: 19097774
Banna GL, Cantale O, Bersanelli M et al (2020) Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm. Oncol Rev 14:490
doi: 10.4081/oncol.2020.490
pubmed: 32782728
pmcid: 7385529
Muñoz-Unceta N, Burgueño I, Jiménez E et al (2018) Durvalumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol 10:1758835918804151
doi: 10.1177/1758835918804151
pubmed: 30344651
pmcid: 6187424
Rofi E, Del Re M, Arrigoni E et al (2019) Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers. Crit Rev Oncol/Hematol 144:102812
doi: 10.1016/j.critrevonc.2019.09.004
pubmed: 31698313
Grande E, Arranz JÁ, De Santis M et al (2024) Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study. Lancet Oncol 25:29–45
doi: 10.1016/S1470-2045(23)00540-5
pubmed: 38101433
Powles T, Csőszi T, Özgüroğlu M et al (2021) Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol 22:931–945
doi: 10.1016/S1470-2045(21)00152-2
pubmed: 34051178
van der Heijden MS, Sonpavde G, Powles T et al (2023) Nivolumab plus Gemcitabine-Cisplatin in advanced urothelial carcinoma. N Engl J Med 389:1778–1789
doi: 10.1056/NEJMoa2309863
pubmed: 37870949
Miyake M, Shimizu T, Nishimura N et al (2022) Response to pembrolizumab after dose-reduced cisplatin plus gemcitabine chemotherapy is inferior to that after carboplatin plus gemcitabine chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma. Clin Genitourin Cancer 20:196.e1-196.e9
doi: 10.1016/j.clgc.2021.11.006
pubmed: 34916166
Kato M, Kobayashi T, Matsui Y et al (2021) Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab. Int J Urol 28:1261–1267
doi: 10.1111/iju.14686
pubmed: 34545627
Galluzzi L, BuquéA KO et al (2017) Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol 17:97–111
doi: 10.1038/nri.2016.107
pubmed: 27748397